Monoclonal Antibody

Open Collage in a new Window

This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Monoclonal_antibodies

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.

Introduction to Monoclonal Antibody

Duration: 5:06
Updated: 30 Aug 2014
author: John Nguyen

This is a brief introduction to monoclonal antibodies (mAb). Design inspired by Salman Khan. Special thanks to Professor DeMasi @ MCPHS University. Science m...

http://wn.com/Introduction_to_Monoclonal_Antibody

Play Fullscreen

Monoclonal Antibody

Duration: 1:34
Updated: 03 Sep 2014
author: John Munro

http://wn.com/Monoclonal_Antibody

Play Fullscreen

Monoclonal antibody

Duration: 1:21
Updated: 09 Aug 2014
author: Random42Medical

Monoclonal antibodies are a growing class of biological agents for the treatment of a variety of diseases. Scientists are now looking at ways to modify their...

http://wn.com/Monoclonal_antibody

Play Fullscreen

Monoclonal antibody

Duration: 5:49
Updated: 08 Feb 2015

This monoclonal antibody lecture explains the production and use of monoclonal antibodies in therapy. For more information, log on to- http://www.shomusbiology.com/ Get Shomu's Biology DVD set here- http://www.shomusbiology.com/dvd-store/ Download the study materials here- http://shomusbiology.com/bio-materials.html

http://wn.com/Monoclonal_antibody

Play Fullscreen

What are Monoclonal Antibodies?

Duration: 2:28
Updated: 01 Mar 2014
author: jd369

A brief explanation of what Monoclonal Antibodies are using the example of Herceptin.

http://wn.com/What_are_Monoclonal_Antibodies?

Play Fullscreen

Cancer treatment using monoclonal antibody

Duration: 9:34
Updated: 02 Sep 2014
author: Suman Bhattacharjee

This cancer therapy video explains the methods of using monoclonal antibodies to treat cancer For more information, log on to- http://shomusbiology.weebly.co...

http://wn.com/Cancer_treatment_using_monoclonal_antibody

Play Fullscreen

Monoclonal Antibody Production [HD Animation]

Duration: 1:38
Updated: 14 Aug 2014
author: Biology / Medicine Animations HD

See an organised list of all the animations: http://doctorprodigious.wordpress.com/hd-animations/

http://wn.com/Monoclonal_Antibody_Production_HD_Animation_

Play Fullscreen

Monoclonal Antibody Production

Duration: 6:08
Updated: 02 Sep 2014
author: John Nguyen

This is a brief overview of the production of monoclonal antibodies (mAb), also known as hybridoma technology. Design inspired by Salman Khan. Special thanks...

http://wn.com/Monoclonal_Antibody_Production

Play Fullscreen

Monoclonal Antibody Production

Duration: 5:50
Updated: 19 Aug 2014
author: Haroon Ahmad

This video describes Monoclonal Antibody Production.

http://wn.com/Monoclonal_Antibody_Production

Play Fullscreen

Monoclonal Antibodies

Duration: 3:03
Updated: 04 Sep 2014
author: Dr.G.Bhanu Prakash

Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a un...

http://wn.com/Monoclonal_Antibodies

Play Fullscreen

Monoclonal Antibodies

Duration: 10:49
Updated: 07 Feb 2015

http://www.aklectures.com/lecture/monoclonal-antibodies https://www.facebook.com/aklectures The website organizes the videos into clear and structured chapters that you can use to watch the videos in sequential and logical order as taught by most educational institutions. Each lecture contains a description along with a customized comment section that you can use to ask questions regarding the topic. Posting questions on the site allows us to answer them much quicker than on YouTube. This site was created for the purpose of providing students access to a quality education in the sciences and we are continually working on improving the website's functionality and features. http://www.aklectures.com

http://wn.com/Monoclonal_Antibodies

Play Fullscreen

A level. S.7 Monoclonal antibodies (Ms Cooper)

Duration: 12:56
Updated: 24 Jul 2014

http://wn.com/A_level._S.7_Monoclonal_antibodies_(Ms_Cooper)

Play Fullscreen

Therapeutic Applications of Monoclonal Antibodies

Duration: 9:23
Updated: 02 Sep 2014
author: John Nguyen

This is a brief introduction to some of the therapeutic applications of monoclonal antibodies. Design inspired by Salman Khan. Special thanks to Professor De...

http://wn.com/Therapeutic_Applications_of_Monoclonal_Antibodies

Play Fullscreen

mr i explains: Antibody Structure, How Monoclonal Antibodies are produced and their use in diagnosis

Duration: 14:09
Updated: 08 May 2014
author: mr i explains

http://wn.com/mr_i_explains_Antibody_Structure,_How_Monoclonal_Antibodies_are_produced_and_their_use_in_diagnosis

Play Fullscreen

Monoclonal Antibody as a Therapeutic Drug!

Duration: 18:24
Updated: 25 Jan 2014
author: TheHiomer

Monoclonal Antibodies i getting more and more in focus of Biotech Companies. Why is that so?

http://wn.com/Monoclonal_Antibody_as_a_Therapeutic_Drug!

Play Fullscreen

Monoclonal Antibodies: Stanford Academia-Industry Collaboration

Duration: 51:16
Updated: 17 Aug 2014
author: Stanford

August 22, 2007 presentation by Ron Levy for the Stanford School of Medicine Medcast lecture series. Ron Levy, MD, professor of Medicine at Stanford, recount...

http://wn.com/Monoclonal_Antibodies_Stanford_Academia-Industry_Collaboration

Play Fullscreen

Targeted Cancer Cell Therapy

Duration: 4:36
Updated: 05 Oct 2012

If you like this animation, LIKE us on Facebook: http://www.nucleusinc.com/facebook http://www.nucleusinc.com/medical-animations This 3D medical animation about targeted cancer cell therapy depicts normal cell division, apoptosis, tumor cell formation, tumor development, and angiogenesis of a tumor. It describes the cause of tumor cell formation at the genetic level with DNA, and metastasis through blood and lymph vessels. This animation covers the various effects of chemotherapy: cancer cell death, tumor death, destruction of normal cells and tissue. Also described are targeted cancer cell treatments, such as, small molecule drugs and monoclonal antibodies. This animation describes the effects of these therapy treatments: block cancer cell signals, toxic substance delivery to cancer cells, immune cell response, blocking growth of new blood vessels that supply tumors.

http://wn.com/Targeted_Cancer_Cell_Therapy

Play Fullscreen

Monoclonal antibodies against flu

Duration: 4:16
Updated: 04 Sep 2014
author: CrucellVideo

Update, December 2013: full description of the mechanism of action of the antibody just published. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjour...

http://wn.com/Monoclonal_antibodies_against_flu

Play Fullscreen

Monoclonal and Polyclonal antibodies

Duration: 7:07
Updated: 26 Aug 2014
author: biologyexams4u

Simplified explanation of monoclonal and polyclonal antibodies For More Immunology Notes :http://www.biologyexams4u.com/2011/09/immunology-notes.html For Mor...

http://wn.com/Monoclonal_and_Polyclonal_antibodies

Play Fullscreen

Monoclonal antibody production using Hybridoma Technology

Duration: 5:54
Updated: 04 Sep 2014
author: biologyexams4u

Monoclonal antibody production using hybridoma technology (Step wise explanation). http://www.biologyexams4u.com/2013/02/what-is-monoclonal-antibody-how-it-i...

http://wn.com/Monoclonal_antibody_production_using_Hybridoma_Technology

Play Fullscreen

How human monoclonal antibodies neutralize the flu virus | Dana-Farber Cancer Institute

Duration: 1:58
Updated: 22 Jun 2014
author: Dana-Farber Cancer Institute

This animation illustrates how directing monoclonal antibodies to the influenza virus prevents a conformational change in the protein that is necessary for v...

http://wn.com/How_human_monoclonal_antibodies_neutralize_the_flu_virus_|_Dana-Farber_Cancer_Institute

Play Fullscreen

Antibody purification Methods

Duration: 7:14
Updated: 22 Jun 2014
author: ajithkumarmanghat

http://technologyinscience.blogspot.com/2013/03/antibody-purification-methods.html Antibody purification is a multistep process by which antibodies with high...

http://wn.com/Antibody_purification_Methods

Play Fullscreen

When will the first monoclonal antibody be approved?

Duration: 3:44
Updated: 16 Apr 2015

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the progress being made with monoclonal antibodies being used to treat myeloma. He highlights three specific ones (daratumumab, Sanofi’s SAR compound, and elotuzumab) and discusses why each is promising. Please subscribe to our channel! Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC Category Nonprofits & Activism License Standard YouTube License

http://wn.com/When_will_the_first_monoclonal_antibody_be_approved?

Play Fullscreen

Development of purification strategies for a diversity of MAb

Duration: 57:21
Updated: 04 Feb 2014
author: gelifesciences

Explore our solutions for MAb development and production at http://www.gelifesciences.com/mabs This webinar explains how to select chromatography media (resi...

http://wn.com/Development_of_purification_strategies_for_a_diversity_of_MAb

Play Fullscreen

Sirukumab, a human anti-interleukin-6 monoclonal antibody

Duration: 20:54
Updated: 09 Apr 2015

This EJournal Club series will engage rheumatologists, and other interested clinicians in an examination, discussion, and assessment of the most recent peer-reviewed literature on rheumatic diseases. Dr. Leonard Calabrese will lead an interactive discussion with the lead author of a top evidence-based journal article. Visit HYPERLINK "http://www.ccfcme.org/ejournalvideos" http://www.ccfcme.org/ejournalvideos to claim CME credit or learn more about E-Journal Club. Sirukumab, a human anti-interleukin-6 monoclonal antibody webcast features Dr. Michael Weinblatt of Harvard University and Dr. Leonard Calabrese, Cleveland Clinic. The video was produced by the Cleveland Clinic Foundation Center for Continuing Education and the Cleveland Clinic RJ Fasenmyer Center for Clinical Immunology. Interested in related CME education? Visit HYPERLINK "http://www.ccfcme.org/ejournalvideos" http://www.ccfcme.org/ejournalvideos Like us on Facebook: HYPERLINK "https://www.facebook.com/CMEClevelandClinic" https://www.facebook.com/CMEClevelandClinic Follow us on Twitter: HYPERLINK "https://twitter.com/cleveclinic_cme" https://twitter.com/cleveclinic_cme

http://wn.com/Sirukumab,_a_human_anti-interleukin-6_monoclonal_antibody

Play Fullscreen

Novel human monoclonal antibodies / Dr Robert Friesen - Crucell - World Vaccine Congress

Duration: 32:07
Updated: 23 May 2014
author: Vaccine Nation

Subscribe: http://www.youtube.com/user/vaccinenation Novel human monoclonal antibodies • Discovery of broadly neutralizing human mAbs against group 1 and 2 I...

http://wn.com/Novel_human_monoclonal_antibodies_Dr_Robert_Friesen_-_Crucell_-_World_Vaccine_Congress

Play Fullscreen

Separation and Characterization of Monoclonal Antibodies and Antibody Fragments

Duration: 28:52
Updated: 02 Apr 2015

If you have any questions, please don't hesitate to contact us at info@sepax-tech.com

http://wn.com/Separation_and_Characterization_of_Monoclonal_Antibodies_and_Antibody_Fragments

Play Fullscreen

Label-Free Assays for High-Throughput Monoclonal Antibody Characterization

Duration: 74:12
Updated: 12 Dec 2013
author: GENNews

For a PDF of the slides, click here: http://bit.ly/17sJjyW During therapeutic antibody development, monoclonal antibody panels are routinely screened for the...

http://wn.com/Label-Free_Assays_for_High-Throughput_Monoclonal_Antibody_Characterization

Play Fullscreen

Monoclonal Antibodies (Charles Barnes, PhD)

Duration: 48:33
Updated: 07 Aug 2014
author: ACAAICOLA

Dr. Charles Barnes reviews the current state of monoclonal antibodies, how they are made and their uses. Held on Dec 2, 2011.

http://wn.com/Monoclonal_Antibodies_(Charles_Barnes,_PhD)

Play Fullscreen

Using the ProteOn™ XPR36 to Characterize Human-Derived Monoclonal Antibodies Against Influenza Virus

Duration: 22:05
Updated: 10 Oct 2013
author: BioRadLifeScience

For more information, visit http://www.bio-rad.com/yt/8/proteonxpr36. Different strains of Influenza virus include a great diversity of antigenic proteins, o...

http://wn.com/Using_the_ProteOn™_XPR36_to_Characterize_Human-Derived_Monoclonal_Antibodies_Against_Influenza_Virus

Play Fullscreen

Flu: Human Monoclonal antibodies- a map guiding towards a universal influenza vaccine?

Duration: 23:34
Updated: 09 Mar 2014
author: Vaccine Nation

Subscribe: http://www.youtube.com/user/vaccinenation A universal influenza vaccine that provides broad protection against both seasonal and pandemic strains ...

http://wn.com/Flu_Human_Monoclonal_antibodies-_a_map_guiding_towards_a_universal_influenza_vaccine?

Play Fullscreen

Antibody Discovery & Recovery: From Genetic Immunization to Recombinant Antibody Production

Duration: 32:27
Updated: 08 May 2014
author: aldevronmedia

Genetic immunization can be utilized to generate antibodies starting with only an antigen's cDNA sequence. This strategy allows researchers to target challen...

http://wn.com/Antibody_Discovery_&_Recovery_From_Genetic_Immunization_to_Recombinant_Antibody_Production

Play Fullscreen

Antibody purification – what you need to know to use antibodies effectively

Duration: 59:44
Updated: 30 Aug 2014
author: InnovaBiosciences

Sources of antibodies Purification techniques – pro's and con's of each Why purification matters How to purify antibodies without expert knowledge If you hav...

http://wn.com/Antibody_purification_–_what_you_need_to_know_to_use_antibodies_effectively

Play Fullscreen

Webinar: Platform Approaches for the Purification of Antibody Fragments

Duration: 52:58
Updated: 04 Feb 2014
author: gelifesciences

Explore our solutions for development and production of antibody fragments at http://www.gelifesciences.com/mabs This webinar presents chromatography media (...

http://wn.com/Webinar_Platform_Approaches_for_the_Purification_of_Antibody_Fragments

Play Fullscreen

Monoclonal Antibodies Complete Primary Structure and Biosimilarity Assessment

Duration: 80:49
Updated: 09 Jun 2014
author: SCIEX part of AB SCIEX

Monoclonal antibodies complete primary structure and biosimilarity assessment in a single analysis using CESI-MS-MS.

http://wn.com/Monoclonal_Antibodies_Complete_Primary_Structure_and_Biosimilarity_Assessment

Play Fullscreen

Camtasia Lecture #27 Monoclonal Antibodies (mAbs)

Duration: 46:12
Updated: 06 Jun 2014
author: tawkaw OpenCourseWare

http://wn.com/Camtasia_Lecture_27_Monoclonal_Antibodies_(mAbs)

Play Fullscreen

Camtasia Lecture #5 Monoclonal Antibodies

Duration: 48:52
Updated: 06 Jun 2014

http://wn.com/Camtasia_Lecture_5_Monoclonal_Antibodies

Play Fullscreen

Identification of Antibodies Directed Against Human Islet Cell Surface Molecules

Duration: 53:39
Updated: 18 Jul 2014
author: ALPCO

Dr. Phil Streeter of Oregon Health Science University presents an overview of a new set of monoclonal antibody reagents used to differentiate and isolate fun...

http://wn.com/Identification_of_Antibodies_Directed_Against_Human_Islet_Cell_Surface_Molecules

Play Fullscreen

New tools and alternatives to streamline your (mAb) purification process

Duration: 57:33
Updated: 25 Jan 2014
author: WTG Webinars

http://www.wtg-ondemand.com/detail_webinar.asp?spcomp=127 As monoclonal antibodies (mAbs) continue to represent a growing proportion of development pipelines...

http://wn.com/New_tools_and_alternatives_to_streamline_your_(mAb)_purification_process

Play Fullscreen

How to overcome assay challenges using custom recombinant antibodies

Duration: 35:23
Updated: 16 Dec 2014

This webinar presented by Technical Sales Specialist, Michael Schwemmlein, demonstrates how custom-made recombinant antibodies can solve challenges when designing and optimizing critical assays to support drug development, diagnostic assays and discovery studies. The presentation shows how AbD Serotec uses the HuCAL® antibody library and phage display technology (http://www.abdserotec.com/custom-monoclonal-antibody-generation.html) to offer a custom antibody service that overcomes the limitations of traditional animal antibody generation methods. Recombinant antibodies can be made that discriminate between the tiniest molecular differences, such as modified and unmodified versions of an antigen (08:26). Guided selection strategies are used to generate anti-idiotypic antibodies for PK, PD and ADA assays (13:30), fully human antibodies as positive controls and calibrators in diagnostic assays (18:17), and antibody sandwich pairs for rapid biomarker discovery and evaluation (20:18). This webinar illustrates our expertise in designing selection strategies for successfully generating such sophisticated specificity requirements. Subscribe to our YouTube channel for more webinars on our HuCAL technology and anti-idiotypic antibodies. Find out more about our webinar here: http://www.abdserotec.com/overcome-your-assay-challenges-with-our-free-webinar.html Twitter: https://twitter.com/AbDSerotec Linkedin: http://www.linkedin.com/company/abd-serotec Website: http://www.abdserotec.com HuCAL® is a registered trademark of MorphoSys AG.

http://wn.com/How_to_overcome_assay_challenges_using_custom_recombinant_antibodies

Play Fullscreen

JCI's Conversations with Giants in Medicine: Napoleone Ferrara

Duration: 30:39
Updated: 04 Aug 2014
author: Journal of Clinical Investigation

Napoleone Ferrara, of the University of California, San Diego, is best known for isolating and cloning vascular endothelial growth factor (VEGF). He then bui...

http://wn.com/JCI's_Conversations_with_Giants_in_Medicine_Napoleone_Ferrara

Play Fullscreen

1st international Antibody Validation Forum 2014: Jan Voskuil

Duration: 30:31
Updated: 30 Oct 2014

Dr Jan Voskuil is Chief Scientific Officer at antibody manufacturer Everest Biotech in Oxfordshire, UK. After specializing in prokaryotic cell biology through his PhD program in Amsterdam, Netherlands, and a postdoc position at Stanford, California, he switched to the science of neurodegenerative diseases at Oxford, UK through postdoc positions at Dunn School of Pathology and at MRC and through a leading position at the Alzheimer drug discovery company Synaptica. He subsequently gained experience in a GLP-regulatory environment in CRO companies both in Oxfordshire and Cambridgeshire, validating assays in Flow Cytometry and ELISA platforms and writing SOPs. His extensive experience with generating and characterizing monoclonal and polyclonal antibodies in combination with accrued knowledge on immunoassays in academic and commercial environments made him the ideal candidate to take charge in putting Everest Biotech on the global map by ever raising the quality and size of its catalogue and by delivery of adequate technical support. As a result, Everest antibodies are currently part of most globally well-known catalogues, and its products are increasingly recognized as useful alternatives to unfit monoclonal antibodies. For more details about 1st international antibody validation forum please check on http://www.stjohnslabs.com/ac_cms/blog

http://wn.com/1st_international_Antibody_Validation_Forum_2014_Jan_Voskuil

Play Fullscreen

Brian Fonslow - Comprehensive characterization of mAbs in a single analysis

Duration: 61:10
Updated: 14 Oct 2014

Watch on LabRoots at http://labroots.com/user/webinars/details/id/356 In this Webinar, we will present a comprehensive characterization of a representative monoclonal antibody trypsin-digest in a single analysis. Both small and large peptides (3–65 amino acids) are separated, identified, and quantified, contributing to 100% sequence coverage. Special emphasis is given to comprehensive, quantitative analysis of glycosylation microheterogeneity. Quantitative analysis of degradative hotspots such as asparagine deamidation, methionine oxidation, glutamic acid cyclization, and C-terminal lysine heterogeneity was also achieved from the same run. The results illustrate the benefits of CESI – the integration of CE and electrospray ionization (ESI) into a single dynamic process within the same device – with high resolution mass spectrometry. The ultra-low flow rate of the system (~20 nL/min) ensures maximal ionization efficiency and dramatically reduces ion suppression. • Obtaining comprehensive heterogeneity, stability, and purity information from a single-enzyme digest in a single run • How ultra-low flow rates reduce ion-suppression bias, increase sensitivity, and expand dynamic range. • Orthogonal technology to status quo

http://wn.com/Brian_Fonslow_-_Comprehensive_characterization_of_mAbs_in_a_single_analysis

Play Fullscreen

Tools and Strategies Driving Cancer Immunotherapy

Duration: 82:39
Updated: 12 Jan 2015

Rockland and The Scientist bring together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy. Topics Covered: Basic concepts underlying immunomodulation for Oncology New drug entities: immunomodulatory agents, vaccines, monoclonal antibodies, and more Challenges in drug development New tools for screening and validation Use of biomarkers for targeted therapies With speakers, Dr. Jedd Wolchok, Chief of Melanoma & Immunotherapeutics Service at Memorial Sloan-Kettering Cancer Center and Dr. Tibor Keler, Senior Vice President and Chief Scientific Officer at Celldex Therapeutics. Established in 1962, Rockland Immunochemicals Inc. is a global biotechnology company manufacturing leading edge research tools for basic, applied and clinical research in functional genomics, gene therapy and drug discovery markets. Rockland is a privately held company which operates a manufacturing facility with antibody and protein production capabilities located near Philadelphia, Pennsylvania, USA. Global markets are supported through a highly specialized network of key distributors. Our laboratories consist of over 60,000 square feet, producing antibodies and antibody-based tools that are used to help define mechanisms underlying cell function and disease.

http://wn.com/Tools_and_Strategies_Driving_Cancer_Immunotherapy

Play Fullscreen

Antibody Therapies for C. difficile

Duration: 34:14
Updated: 01 Jun 2014
author: American Society for Microbiology

Clostridium difficile infection is an important cause of intestinal disease, primarily affecting hospitalized patients exposed to antibiotics. Infection has ...

http://wn.com/Antibody_Therapies_for_C._difficile

Play Fullscreen

Necitumumab in NSCLC

Duration: 4:35
Updated: 06 May 2015

Anne S. Tsao, MD, and Roy S. Herbst, MD, examine the use of monoclonal antibody necitumumab in individuals with squamous cell non-small cell lung cancer (NSCLC).

http://wn.com/Necitumumab_in_NSCLC

Play Fullscreen

Advances in monoclonal antibody therapy for multiple myeloma

Duration: 3:36
Updated: 06 May 2015

At the Myeloma 2015 meeting, Dr Joseph Mikhael (Mayo Clinic, Scottsdale, AZ) discusses the development of monoclonal antibodies (mAbs), including anti-CD38 mAbs, SAR650984 and daratumumab, and anti-SLAMF7 mAb, elotuzumab, for the treatment of multiple myeloma. Clinical results to date suggest these monoclonal antibodies are likely to operate synergistically with other therapies.

http://wn.com/Advances_in_monoclonal_antibody_therapy_for_multiple_myeloma

Play Fullscreen

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

Duration: 4:57
Updated: 05 May 2015

Dr David Bajor, (University of Pennsylvania, Philadelphia, USA) talks to ecancertv at AACR 2015 about combining the immunostimulatory anti-CD40 monoclonal antibody CP- 870,893 with the immune checkpoint inhibitor tremelimumab in advanced melanoma. This approach was found to be safe, with clinical evidence of response.

http://wn.com/Investigational_immunotherapy_drug_combo_safe_with_early_signs_of_effectiveness_in_advanced_melanoma

Play Fullscreen

Dr. Post Talking About Monoclonal Antibody

Duration: 5:08
Updated: 27 Apr 2015

Monoclonal antibodies, have revolutionized the treatment of lymphoma in people. We hope that monoclonal antibodies will do the same, and revolutionize the treatment of lymphoma in dogs. Monoclonals will work in a completely different mechanism than will chemotherapy. So, theoretically, even if a cancer is resistant to multiple different types of chemotherapy, it may still respond to a monoclonal antibody.

http://wn.com/Dr._Post_Talking_About_Monoclonal_Antibody

Play Fullscreen

MMB045 - Monoclonal Antibody Protocols Free Ebook

Duration: 3:36
Updated: 26 Apr 2015

http://tinyurl.com/AmbroseKetterling884 Monoclonal Antibody Protocols Methods of Immunization to Enhance the Immune Response to Specific Antigens InVivo in Preparation for Fusions Yielding Monoclonal Antibodies Jon A Rudbach, John L. Cantrell, and J. II Ulrich 1. Introduction The first step in preparing useful monoclonal antibodies (MAbs) is to immunize an animal with an appropriate “vaccine.” Animal and vaccine are both emphasized in the preceding sentence because this chapter describes how to generate satisfactory MAbs by maximizing interactions between the two. The term vaccine was used purposefully to connote that not only antigens of interest may be contained in the immunizing product, but carriers and adjuvants may also be included. These latter components can influence greatly the success of obtaining useful hybri- domas, which produce antibodies of the desired specificity and quality. Immunization protocols for obtaining only murine MAbs are covered herein. Although cross-species hybridizations can be made, they usually involve very specialized techniques. Moreover, the lessons that can be derived from mouse immunization protocols can, in general, be extrapo- lated to other species as well. When considering which mouse strains to immunize, even though some initial advantage may be obtained by selecting a strain other than a Balb/c, there is an overriding consideration that must be taken into From. Methods m Molecular Bology, Vol. 45’ Monoclonal Antrbody Protocols Edlted by W C Davis Inc., Totowa, NJ 2 Rudbach, Cantrell, and Ulrich Download this e-book now.

http://wn.com/MMB045_-_Monoclonal_Antibody_Protocols_Free_Ebook

Play Fullscreen

Agonistic monoclonal antibody Meaning

Duration: 0:38
Updated: 24 Apr 2015

Video shows what agonistic monoclonal antibody means. A monoclonal antibody that aims to boost the human immune system either to fight infection or cancer.. Agonistic monoclonal antibody Meaning. How to pronounce, definition audio dictionary. How to say agonistic monoclonal antibody. Powered by MaryTTS, Wiktionary

http://wn.com/Agonistic_monoclonal_antibody_Meaning

Play Fullscreen

Monoclonal Meaning

Duration: 0:28
Updated: 24 Apr 2015

Video shows what monoclonal means. genetically engineered from a single clone; used especially of a protein or antibody. Monoclonal Meaning. How to pronounce, definition audio dictionary. How to say monoclonal. Powered by MaryTTS, Wiktionary

http://wn.com/Monoclonal_Meaning

Play Fullscreen

Monoclonal antibody Meaning

Duration: 0:36
Updated: 24 Apr 2015

Video shows what monoclonal antibody means. A protein genetically engineered from a single clone of a B cell, especially one produced by fusion with a tumor cell and intended for use as a drug.. Monoclonal antibody Meaning. How to pronounce, definition audio dictionary. How to say monoclonal antibody. Powered by MaryTTS, Wiktionary

http://wn.com/Monoclonal_antibody_Meaning

Play Fullscreen

Global Cancer Monoclonal Antibody Partnering 2010-2015

Duration: 1:40
Updated: 15 Apr 2015

Market Research Reports, Inc. has announced the addition of “Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, players, financials and forecasts” research report to their offering. See more at- http://mrr.cm/4Q4

http://wn.com/Global_Cancer_Monoclonal_Antibody_Partnering_2010-2015

Play Fullscreen

Antibody-based Regimens and their Potential Impact on Clinical Outcomes

Duration: 15:00
Updated: 13 Apr 2015

Dr. Torben Plesner discusses “Antibody-based regimens and their potential impact on clinical outcomes” presented during the satellite symposium Enhancing Clinical Outcomes in Relapsed/Refractory Multiple Myeloma at the 11th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice. Within this educational activity, Dr. Plesner discusses the mechanisms of action, the molecular targets of monoclonal antibody therapies and their therapeutic impact on clinical outcomes through the review and analysis of pertinent clinical studies utilizing antibody-based regimens in patients with relapsed/refractory multiple myeloma. Earn accreditation for this activity at the following location: http://elc.imedex.com/Shared/Services/ActivityRedirect.aspx?activityId=7154 © 2015 Imedex, LLC.

http://wn.com/Antibody-based_Regimens_and_their_Potential_Impact_on_Clinical_Outcomes

Play Fullscreen

Biosimilar Monoclonal Antibodies Market 2015-2025 Report

Duration: 0:21
Updated: 13 Apr 2015

Biosimilar therapeutic antibodies – see why originator companies should now fear those competitors, discovering their trends and potential sales What’s the future of biosimilar antibody therapies (mAbs)? Can that emerging market, with vast potential, achieve expected sales growth? See what’s likely there, staying ahead. Now, in an updated study, you explore that industry’s research and development (R&D;). And assess forecasted revenues. So discover where the money lies from 2015, hearing where those drug producers, their technologies and products head. There avoid struggles to get business information. Instead read on to explore those companies and their medicines, also seeing how that industry’s sales can soon multiply. Forecasts and other analysis to help your research, knowledge and influence Visiongain’s new guide predicts those revenues to 2025 at overall world, class (molecule), product and national level. Its purpose is to help you stay ahead on companies, data, news, opportunities and analysis for those follow-on protein pharmaceuticals. So examine developments underpinning those treatments’ future performance. Assess medical, technological and commercial trends, results and potentials: • Why will the biosimilar mAbs market expand fast from 2015 to 2025, and what limits its sales growth? • When will that industry achieve multibillion dollar revenues, and what’s possible? • What compounds and products – follow-on biologics – give the most promise to developers, producers and sellers? • Who are the best-placed companies for revenue generation there from 2015? • Where lie the best geographical prospects for selling those biological drugs? • How will companies approach opportunities and challenges in serving regulators, doctors, patients and payers? Besides multilevel revenue predictions to 2025, our work presents historical results, market shares and discussions. You get 73 tables, 56 charts and four research interviews with companies and other authorities. For more information please contact Sara Peerun at sara.peerun@visiongainglobal.com or visit https://www.visiongain.com/Report/1379/Biosimilar-Monoclonal-Antibodies-World-Industry-and-Market-Outlook-2015-2025

http://wn.com/Biosimilar_Monoclonal_Antibodies_Market_2015-2025_Report

Play Fullscreen

Evolution of Monoclonal Antibody Treatments for Migraines

Duration: 0:51
Updated: 25 Mar 2015

An Exciting Time For Migraine Management: http://www.clinicalpainadvisor.com/exciting-time-for-migraine-management/article/404785/ NATIONAL HARBOR - The next few years hold promise for "exciting" developments in treating migraines, according to Peter J. Goadsby, MD, of the University of California San Francisco. The evolution of monoclonal antibody treatment represents an important development for treating migraines, Goadsby told Clinical Pain Advisor.

http://wn.com/Evolution_of_Monoclonal_Antibody_Treatments_for_Migraines

Play Fullscreen

Polyclonal vs. Monoclonal vs. Sunshine Antibodies (Immunoaffinity purified polyclonal)

Duration: 1:43
Updated: 11 Mar 2015

Ever wondered what's the difference between a polyclonal antibody and monoclonal antibody, better yet with a Sunshine antibody (immunoaffinity purified polyclonal antibody)? Outlined in this what’s cracking blog post, here are a small animation and the key elements (advantages) for an informed decision on your next antibody purchase! http://blog.ibiosolutions.com/polyclonal-vs-monoclonal-vs-immunoaffinity-purified-polyclonal

http://wn.com/Polyclonal_vs._Monoclonal_vs._Sunshine_Antibodies_(Immunoaffinity_purified_polyclonal)

Play Fullscreen

Monoclonal Antibody Production [HD Animation]

Duration: 11:09
Updated: 06 Feb 2015

This is a brief overview of the production of monoclonal antibodies (mAb), also known as hybridoma technology. Design inspired by Salman Khan. Special thanks. See an organised list of all the animations: This video describes Monoclonal Antibody Production. Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a un. Monoclonal antibody production using hybridoma technology (Step wise explanation).

http://wn.com/Monoclonal_Antibody_Production_HD_Animation_

Play Fullscreen

Dr Ola Landgren at ASH 2014: Therapeutic monoclonal antibodies in myeloma

Duration: 2:36
Updated: 27 Jan 2015

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren (Memorial Sloane Kettering Cancer Center, New York, NY) discusses the development of therapies with novel monoclonal antibodies in multiple myeloma, including antibodies that target CD38, CS1 and PD-1.

http://wn.com/Dr_Ola_Landgren_at_ASH_2014_Therapeutic_monoclonal_antibodies_in_myeloma

Play Fullscreen

Introduction to Monoclonal Antibody

Duration: 9:23
Updated: 24 Jan 2015

monoclonal antibody production, monoclonal antibody production animation, monoclonal antibody production using hybridoma technology, monoclonal antibody therapy, monoclonal antibody animation, monoclonal antibody cancer, monoclonal antibody purification, human monoclonal antibody, polyclonal vs monoclonal antibody, monoclonal antibody production, monoclonal antibody production animation, monoclonal antibody production using hybridoma technology, monoclonal antibody therapy, monoclonal antibody animation, monoclonal antibody cancer, monoclonal antibody purification, monoclonal antibody animation, monoclonal antibody cancer, monoclonal antibody production, monoclonal antibody production animation, monoclonal antibody production using hybridoma technology, monoclonal antibody purification, monoclonal antibody therapy

http://wn.com/Introduction_to_Monoclonal_Antibody

Play Fullscreen

Introduction to Monoclonal Antibody

Duration: 5:06
Updated: 24 Jan 2015

http://wn.com/Introduction_to_Monoclonal_Antibody

Play Fullscreen

ESMO 2014: The anti-PD-L1 monoclonal antibody, MEDI4736, in treating solid tumours

Duration: 2:14
Updated: 15 Jan 2015

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Rachel Humphrey (Senior Vice President, Head of Immuno-Oncology, AstraZeneca) discusses the anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, MEDI4736, which is being evaluated in phase I/II studies in patients with various advanced solid tumour types. The combination of MEDI4736 with the anti-cytotoxic T-lymphocyte-associated protein 4 (CTL-4) monoclonal antibody, tremelimumab, is being studied in patients with non-small cell lung cancer.

http://wn.com/ESMO_2014_The_anti-PD-L1_monoclonal_antibody,_MEDI4736,_in_treating_solid_tumours

Play Fullscreen

photo: AP / Ritchie B. Tongo

This areal photo taken through a glass window of a military plane shows China's alleged on-going reclamation of Mischief Reef in the Spratly Islands in the South China Sea Monday, May 11, 2015.

Edit

US demands immediate halt to South China Sea reclamations

Deccan Herald

30 May 2015

The United States today called for an "immediate and lasting halt" to reclamation works in disputed waters in the South China Sea, saying Beijing's behaviour in the area was "out of step" with international norms. "First, we want a peaceful resolution of all disputes ... "Yet, one country has gone much farther and much faster than any other. "And that's China ... And China did so in only the last 18 months," Carter said ... ....

photo: AP / Mehmet Shakir

File - In this picture taken on Saturday April 18, 2015, a Kurdish displaced family sit in the open air field near their house which was destroyed during the battle between the U.S. backed Kurdish forces and the Islamic State fighters, in Kobani, north Syria.

Edit

Isis in Palmyra: Civilians rounded-up and forced to watch execution of 20 men at amphitheatre

The Independent

28 May 2015

Isis rounded up civilians trapped in Palmyra and forced them to watch 20 people be executed in the historic city’s ancient amphitheatre, a Syrian monitoring group has claimed. The Britain-based Syrian Observatory for Human Rights said the men were accused of having fought for President Bashar Assad's army. It is not known how they were killed ... pic.twitter.com/7tgv1ajjjI ; frederic Helbert (@FredericHelbert) May 27, 2015 ... --> ... Sport ... News ... ....

photo: White House / Pete Souza

File - President Barack Obama talks with Prime Minister Benjamin Netanyahu of Israel as they walk from the Oval Office to the South Lawn Drive of the White House, following their meetings, May 20, 2011.

Edit

Greater-Nuclear Israel and U.S.' GWOT Bombed Nuclear-Free ME Proposal

WorldNews.com

27 May 2015

Article by WN.com Correspondent Dallas Darling. Not only are nuclear weapons the most terrifying weapon ever created by humankind, but they are the most indiscriminate and genocidal ... In other words, the Jews of modern-day Israel will never be like the Jews in the Holocaust. Israel will always be able to visit a terrible retribution on those who threaten them and their expansionist goals.(1) ... Additionally, the U.S ... regimes ... Bomb Scare ... 53....

photo: GNU / photographed by Mia & Lana's dad for www.sarahgeronimo.com

Edit

Are Sarah Geronimo & Matteo Guidicelli preparing for their future?

The Examiner

29 May 2015

As of this morning, May 29 (Manila Time) or this evening, May 28 (California, United States Time) actor/athlete Matteo Guidicelli is in Bohol. His latest Instagram post confirmed that he will stay there for three days for an event he called Giro D Luca ... An indie film for Matteo and a mainstream movie for Sarah Geronimo ... ....

« back to news headlines

Edit

Trillium Announces Voting Results From The Annual Meeting Of Shareholders (Trillium Therapeutics Inc)

noodls

30 May 2015

The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system ... The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors....

Edit

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients Results from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press program of the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)

PR Newswire

30 May 2015

Daratumumab is an investigational human IgG1k monoclonal antibody (mAb) that binds with high affinity to the transmembrane ectoenzyme, CD38, on the surface of multiple myeloma cells....

Edit

New Immunotherapies for Multiple Hard-to-Treat Cancers (ASCO - American Society of Clinical Oncology)

noodls

30 May 2015

(Source. ASCO - American Society of Clinical Oncology) ... Studies include. A phase II study reports that a specific genomic abnormality called mismatch repair (MMR) deficiency predicts response to the anti-PD-1 antibody pembrolizumab ... Approximately one in five patients responded to this immunotherapy. A new study identifies a promising role for the anti-PD-1 antibody pembrolizumab in patients with head and neck cancer ... Media Resources.....

Edit

J&J; multiple myeloma drug offers hope after others stop working -study

Reuters

30 May 2015

J&J; plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and Drug Administration, which can help speed the approval process ... Lonial said this was the first antibody drug that demonstrated effectiveness against myeloma without having to be combined with other medicines ... Trending On Reuters. Photos of the day ... X. ....

Edit

Genentech's Gazyva® Extended the Time People With Refractory Indolent Non-Hodgkin's Lymphoma Lived Without Their Disease Worsening

Stockhouse

30 May 2015

Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on B-cells ... Gazyva is thought to have an increased ability to induce direct cell death and induces greater activity in how it recruits the body’s immune system to attack B-cells (antibody dependent cellular cytotoxicity; ADCC) when compared to Rituxan....

Edit

$16-million boost for research (Queen's University)

noodls

30 May 2015

(Source. Queen's University). Over $16 million in funding from the Canada Foundation for Innovation's (CFI) 2015 Innovation Fund will support research projects in dark matter, cardiology, chemistry and nanotechnologies ... There are also significant potential applications in medical diagnostics, biosensing and chemotherapy as the coating can be modified to interface with antibodies, proteins and viruses. Dr ... distributed by ... (noodl. 28476868) ....

Edit

Pilot Clinical Trial Finds Injected Immune Cells Safe in Multiple Myeloma Patients (Johns Hopkins Health System)

noodls

30 May 2015

(Source. Johns Hopkins Health System) Fast Facts.. Multiple myeloma treatment of immune cells grown from patients' own bone marrow found safe. Several U.S ... The scientists retrieved MILs from each patient's bone marrow, grew them in the laboratory to expand their numbers, activated them with microscopic beads coated with immune activating antibodies and intravenously injected each of the 22 patients with their own cells ... Rosner, C ... (noodl....

Edit

$10 million in new funding adds innovative dimensions to Alzheimer's disease prevention trial (Alzheimer's Association)

noodls

30 May 2015

(Source. Alzheimer's Association) FOR IMMEDIATE RELEASE. CONTACT. Alzheimer's Association media relations, 312.335.4078, media@alz.org ... The award to ... Reiman ... The first treatment is an active immunotherapy aimed at triggering the body's immune system to produce antibodies that block different forms of the amyloid protein, which many researchers believe plays a critical role in the development of Alzheimer's ... Tariot ... For ... Learn more at....

Edit

Collaborative group phase III study shows Roche’s Avastin improves survival in patients with mesothelioma - a devastating type of thoracic cancer (Roche Holding AG)

noodls

30 May 2015

(Source. Roche Holding AG). Basel, 30 May 2015 ... Roche (SIX. RO, ROG; OTCQX ... The data will be presented at the 51st annual meeting of the American Society of Clinical Oncology (ASCO) in an oral session by Professor Gérard Zalcman, M.D., President of the French Collaborative Thoracic Intergroup (Abstract 7500, Saturday 30th May at 15.00 pm CDT).1 ... About the MAPS study1 ... Avastin is an antibody that precisely targets and inhibits VEGF ... (noodl....

Edit

Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival Data from pivotal study for eribulin to be presented during oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire

30 May 2015

WOODCLIFF LAKE, N.J., May 30, 2015 /PRNewswire/ -- Eisai Inc ... CT (Abstract No. LBA10502) ... "These results are important in a disease where so few treatment options exist." ... Median PFS was 2.6 months in both arms ... About Soft Tissue Sarcoma ... Important Safety Information ... Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs....

Edit

The element that can make bones glow

BBC News

30 May 2015

By Laurence Knight BBC News . 30 May 2015. From the section Magazine. Photo. Science Photo Library. Scientists spent years searching for Technetium, a chemical element that came, in time, to play a crucial role in medical diagnosis ... "It is an element beloved of chemists," explains chemist Andrea Sella of University College London, "because almost none of us has seen it" ... Photo ... Photo ... We can use antibodies, and then it becomes very targeted."....

Edit

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia Phase 3 data (abstract LBA7005) featured in the official press program of the 51st annual meeting of the American Society of Clinical Oncology

PR Newswire

30 May 2015

CT ... and Pharmacyclics LLC ... 13.3 months; HR. 0.203, 95% CI ... 22.6%) ... IMBRUVICA works by blocking a specific protein called Bruton's tyrosine kinase (BTK).1 The BTK protein transmits important signals that tell B cells to mature and produce antibodies and is needed by specific cancer cells to multiply and spread.1,2 IMBRUVICA targets and blocks BTK, inhibiting cancer cell survival and spread.1 For more information, visit www.IMBRUVICA.com ... ... ....

Edit

Trillium Announces Voting Results From the Annual Meeting of Shareholders

Stockhouse

29 May 2015